Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Neuroendocrine Tumors Unresectable · Neuroendocrine Tumor Metastatic · Gastroenteropancreatic Neuroendocrine Tumor · Bronchial Neuroendocrine Tumor · Paraganglioma · Pheochromocytoma · Meningioma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
2 insiders sold shares within a month
Since Sep 4, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 300 (planned)
- Started
- Sep 27, 2023
- Main results expected
- Nov 26, 2029
- Fully finished
- Dec 26, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with dose-limiting toxicities (DLTs) after the first administration of [212Pb]VMT-α-NET
Measured over: Incidence and severity of DLTs during the first 42 days of study treatment will be assessed.
Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 in subjects with NETs
Measured over: Up to week 96
ORR per Response Assessment in Neuro-Oncology (RANO) meningioma criteria in subjects with meningioma
Measured over: Up to week 96
Number of subjects with adverse events (AEs)
Measured over: Until the end of study (3 years after end-of-study visit)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.8, since 2026-09-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05636618 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC